Eli Lilly’s donanemab Alzheimer’s drug delayed by FDA
The U.S. Meals and Drug Administration has delayed motion for the promising Alzheimer’s therapy donanemab, the drug producer stated on Friday. Eli Lilly stated the FDA would wait on ruling about donanemab, a drug for older folks with early signs of Alzheimer’s illness, till after the primary quarter of 2024 whereas the federal company convenes
Read More